Противовирусная терапия гепатита с циррозом печени

Противовирусная терапия гепатита с циррозом печени

1. Brown RS. Hepatitis C and liver transplantation. Nature 2005;436:973–78.

2. Muhlberger N, Schwarzer R, Lettmeier B, et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009;9:34.

3. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virusrelated graft cirrhosis after liver transplantation. Hepatology 2000;32:852–58.

4. Wiesner RH, Sorrell M, Villamil F. The international liver transplantation society expert. Report of the first international liver transplantation society expert panel consensus Conference on liver transplantation and hepatitis C. Liver Transpl 2003;9:S1–S9.

5. Rowe IA, Webb K, Gunson BK, et al. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008;21:459–65.

6. Огурцов П.П., Мазурчик Н.В. Современные подходы к лечению вирусных циррозов перед трансплантацией печени // Гепатологический форум 2007. № 1. С. 12–20.

7. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335–74.

8. Iacobellis A, Ippolito A, Andriulli A. Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition. World J Gastroenterol 2008;14:6467–72.

9. Iacobellis A, Andriulli A. Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection. Expert Opin. Pharmacother 2009;10:1929–38.

10. Peveling-Oberhag J, Zeuzem S, Hofmann WP. Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med Microbiol Immunol 2010; 199:1–10.

11. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975–82.

12. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–65.

13. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008;149:399–403.

14. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver Wbrosis in patients with chronic hepatitis C. Gastroenterology, 2002;122:1303–13.

15. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced firosis. Ann Intern Med 2007;147:677–84.

16. Pol S, Carnot F, Nalpas B, et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol 2004;35:107–12.

17. Serpaggi J, Carnot F, Nalpas B, et al. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol 2006;37:1519–26.

18. Everson GT, Balart L, Lee SS, et al. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther 2008;27:542–51.

19. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alfa is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45:579–87.

20. Braks RE, Ganne-Carrie N, Fontaine H, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007;13:5648–53.

21. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673–80.

22. Abergel A, Hezode C, Leroy V, et al. French multicenter study group. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial compared two doses of peginterferon alpha-2b. J Viral Hepat 2006; 13:811–20.

23. Helbling B, Jochum W, Stamenic I, et al. HCVrelated advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon a-2a and ribavirin. J Viral Hepat 2006; 13:762–69.

24. Syed E, Rahbin N, Weiland O, et al. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis. Scand J Gastroenterol 2008;43:1378–86.

25. Roffi L, Colloredo G, Pioltelli P, et al. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antivir Ther 2008;13:663–73.

26. Floreani A, Baldo V, Rizzotto ER, et al. Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis. J Clin Gastroenterol 2008;42:734–37.

27. Marrache Y, Consigny MP, Ripault D, et al. Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. J Viral Hepat 2005; 12:421–28.

28. Aghemo A, Rumi MG, Soffredini R, et al. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. Antivir Ther 2006;11:797–802.

29. Moreno Lopez R, Sicilia Aladren B, Gomollon Garcia F. Use of agents stimulating erythropoiesis in digestive diseases. World J Gastroenterol 2009;15:4675–85.

30. Antonini MG, Babudieri S, Maida I, et al. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Infection 2008;36:250–55.

31. Cooper CL, Al-Bedwawi S, Lee C, et al. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006;42:1674–78.

32. Koirala J, Gandotra SD, Rao S, et al. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepatol 2007;14:782–87.

33. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227–36.

34. Di Marco V, Almasio PL, Ferraro D, et al. Peginterferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007;47:484–91.

35. Di Bisceglie AM, ShiVman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359:2429–41.

36. Bruix J, Poynard T, Colombo M, et al. PegIntron maintenance therapy in cirrhotic (METAVIR F4) HCV patients, who failed to respond to interferon/ ribavirin therapy: Wnal results of the EPIC3 cirrhosis maintenance trial. J Hepatol 2009;50(Suppl.):49.

37. Afdhal NH, Levine R, Brown R, et al. Colchicine versus PEG-interferon alfa 2b long term therapy: results of the 4 year copilot trial. J Hepatol 2008;48(Suppl.):3.

38. Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002;8:350–55.

39. Thomas RM, Brems JJ, Guzman-Hartman G, et al. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003;9:905–15.

40. Forns X, Garcнa-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003;39:389–96.

41. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005;42:255–62.

42. Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007;46:206–12.

43. Annicchiarico BE, Siciliano M, Avolio AW, et al. Treatment of chronic hepatitis C virus infection with pegylated interferon and ribavirin in cirrhotic patients awaiting liver transplantation. Transplant Proc 2008;40:1918–20.

44. Tekin F, Gunsar F, Karasu Z, et al. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics. Aliment Pharmacol Ther 2008; 27:1081–85.

45. Iacobellis A, Siciliano M, Annicchiarico BE, et al. Sustained virologic responses following standard antiviral therapy in decompensated HCVinfected cirrhotic patients. Aliment Pharmacol Ther 2009;30:146–53.

46. Carrion JA, Martinez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009;50:719–28.

47. Forns X, Bruix J. Treating hepatitis C in patients with cirrhosis: the effort is worth it. J Hepatol 2010;52:624–26.

48. Davis GL, Nelson DR, Terrault N, et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin in liver transplant recipients. Liver Transpl 2005;11:941–49.

49. Schiano TD, Charlton M, Younossi Z, et al. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl 2006;12:1381–89.

50. Forestier N, Zeuzem S. Novel hepatitis C drugs in current trials. Clin Liver Dis 2008;12:529–55.



Источник: pharmateca.ru


Добавить комментарий